01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
Businesses around the world have been substantially impacted by the COVID-19 pandemic and are likely...
Read More >
Following the recently announced three-month delay to notice and contribution requirements, and the ...
Read More >
On November 20, 2019, the California Supreme Court finally agreed to take up the question of whether...
Read More >
The Department of Treasury’s office that administers reviews of foreign investments in U.S. compani...
Read More >
Associates’ voices matter in hiring decisions—at some firms more than others, but at all firms, at...
Read More >
Seyfarth Synopsis: St. Louis has become the third locality in Missouri to enact a “Ban the Box” la...
Read More >